Evidence map›Paper›PMID 36978896›Full record

ArticleAntioxidants (Basel, Switzerland)2023

AD-1 Small Molecule Improves Learning and Memory Function in Scopolamine-Induced Amnesic Mice Model through Regulation of CREB/BDNF and NF-κB/MAPK Signaling Pathway.

Rengasamy Balakrishnan, Ju-Young Park, Duk-Yeon Cho, Jae-Yong Ahn, Dong-Sun Yoo, Sang-Ho Seol, Sung-Hwa Yoon, Dong-Kug Choi

Open access · goldFull text read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Electromechanically induced membrane restructuring enables learning and memory.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Ibrain · 2025
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rengasamy BalakrishnanDepartment of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea.ORCID 0000-0001-8135-8183
Ju-Young ParkDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
Duk-Yeon ChoResearch and Development, Sinil Pharmaceutical Co., Ltd., & APIMEDS Inc. Room 608 Namseong Plaza Building, Digital-ro 130 Geumcheon-gu, Seoul 08589, Republic of Korea.
Jae-Yong AhnDepartment of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea.
Dong-Sun YooResearch and Development, Sinil Pharmaceutical Co., Ltd., & APIMEDS Inc. Room 608 Namseong Plaza Building, Digital-ro 130 Geumcheon-gu, Seoul 08589, Republic of Korea.
Sang-Ho SeolResearch and Development, Sinil Pharmaceutical Co., Ltd., & APIMEDS Inc. Room 608 Namseong Plaza Building, Digital-ro 130 Geumcheon-gu, Seoul 08589, Republic of Korea.
Sung-Hwa YoonDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
Dong-Kug ChoiDepartment of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea.ORCID 0000-0001-7041-1524
Konkuk University · KRAjou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive decline and memory impairment induced by oxidative brain damage are the critical pathological hallmarks of Alzheimer's disease (AD). Based on the potential neuroprotective effects of AD-1 small molecule, we here explored the possible underlying mechanisms of the protective effect of AD-1 small molecule against scopolamine-induced oxidative stress, neuroinflammation, and neuronal apoptosis. According to our findings, scopolamine administration resulted in increased AChE activity, MDA levels, and decreased antioxidant enzymes, as well as the downregulation of the antioxidant response proteins of Nrf2 and HO-1 expression; however, treatment with AD-1 small molecule mitigated the generation of oxidant factors while restoring the antioxidant enzymes status, in addition to improving antioxidant protein levels. Similarly, AD-1 small molecule significantly increased the protein expression of neuroprotective markers such as BDNF and CREB and promoted memory processes in scopolamine-induced mice. Western blot analysis showed that AD-1 small molecule reduced activated microglia and astrocytes via the attenuation of iba-1 and GFAP protein expression. We also found that scopolamine enhanced the phosphorylation of NF-κB/MAPK signaling and, conversely, that AD-1 small molecule significantly inhibited the phosphorylation of NF-κB/MAPK signaling in the brain regions of hippocampus and cortex. We further found that scopolamine promoted neuronal loss by inducing Bax and caspase-3 and reducing the levels of the antiapoptotic protein Bcl-2. In contrast, AD-1 small molecule significantly decreased the levels of apoptotic markers and increased neuronal survival. Furthermore, AD-1 small molecule ameliorated scopolamine-induced impairments in spatial learning behavior and memory formation. These findings revealed that AD-1 small molecule attenuated scopolamine-induced cognitive and memory dysfunction by ameliorating AChE activity, oxidative brain damage, neuroinflammation, and neuronal apoptosis.

Indexed as

AD−1 small moleculeapoptosismemory impairmentneuroinflammationoxidative stressscopolamine

Identifiers

PMID36978896
PMCPMC10045324
OpenAlexW4323319013

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read77
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.